Andrea Lobo,  —

Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto, in drug addiction, studying neuronal plasticity induced by amphetamines. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, from stroke, gene regulation, cancer, and rare diseases. She authored multiple research papers in peer-reviewed journals. She shifted towards a career in science writing and communication in 2022.

Articles by Andrea Lobo

Dosing begins in Phase 3 trial of Parkinson’s therapy solengepras

A Phase 3 clinical trial evaluating investigational oral therapy solengepras as a treatment for Parkinson’s disease has dosed its first patient. The ARISE trial (NCT06553027) is evaluating the efficacy of solengepras as a potential add-on therapy to levodopa and other Parkinson’s medications. Patient recruitment is ongoing…

Vivolta, Neurochase team on blood-brain barrier drug delivery system

Vivolta and Neurochase have partnered to manufacture specialized micro-catheters using the former’s medical electrospinning  (MediSpin) technology to deliver therapies directly to specific brain regions for neurological conditions like Parkinson’s disease. The technology would enhance Neurochase’s Convection Enhanced Delivery (CED) system, which is designed to allow…

Vaccine for early Parkinson’s showing safety in Phase 2 trial

ACI-7104, an investigational vaccine to treat people in the early stages of Parkinson’s disease, is showing safety and tolerability in a Phase 2 clinical trial, while also inducing the production of anti-alpha-synuclein antibodies at high levels, according to interim trial findings. Being developed by AC Immune,…

C-Path effort to boost Parkinson’s disease gender-equitable therapies

The Critical Path Institute (C-Path) is launching a new initiative to advance research on how Parkinson’s disease impacts women and people across the gender spectrum. The goal is to develop treatments and technologies that take into account each person’s unique experience with the disease, leading to more equitable approaches for…

Inventor of device for hand mobility wins Ali Humanitarian Award

Lianna Genovese, the 25-year-old founder of Imaginable Solutions and the inventor of Guided Hands, a device that helps individuals with limited hand mobility, was recognized with the 2024 Muhammad Ali Humanitarian Award. Various conditions can limit a person’s ability to write, draw, dress themselves, or use technology, including…

Sunbird Bio blood test may yield accurate Parkinson’s diagnosis

Sunbird Bio’s blood test to indirectly detect toxic clumps of alpha-synuclein protein in the brain, a hallmark of Parkinson’s disease, may help yield an accurate Parkinson’s diagnosis, according to data from a clinical study. The company presented the results in a poster, “Using neural derived EV-bound biomarkers in…

Device that assesses brain activity may help diagnose Parkinson’s

Delphi-MD, a system that measures brain activity, may be used for the early diagnosis of Parkinson’s disease and for differentiating between its subtypes, particularly those marked by rapid disease progression, a study shows. The technology, developed by Quantalx Neuroscience, provides direct, real-time imaging of the brain’s electrical…

SandboxAQ joins MJFF initiative to target Parkinson’s LRRK2 gene

SandboxAQ has signed a $25 million research grant through an initiative of The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to develop new treatments that target the LRRK2 gene, mutations in which are one of the most common genetic causes of Parkinson’s disease. Under the partnership, which…